{
    "symbol": "NTNX",
    "quarter": 4,
    "year": 2022,
    "date": "2022-08-31 21:08:16",
    "content": " The guidance for Q1 \u00e2\u0080\u009823 is as follows: ACV billings of $210 million to $215 million, a year-over-year growth of 16% at the midpoint; revenue of $410 million to $415 million, year-over-year growth of 9% at the midpoint; non-GAAP gross margin of approximately 82%; non-GAAP operating margin of approximately negative 6% with non-GAAP operating expenses of $360 million to $365 million; weighted average shares outstanding of approximately $229 million. The guidance for fiscal year \u00e2\u0080\u009823 is as follows: ACV billings of $895 million to $900 million, year-over-year growth of 19% at the midpoint; revenue of $1.77 billion to $1.78 billion, year-over-year growth of 12% at the midpoint; non-GAAP gross margin of approximately 82%; non-GAAP operating margin of approximately 2% with non-GAAP operating expenses of $1.41 billion to $1.42 billion."
}